BTIG sets USD 6.00 target for DarioHealth stock

Published on 10/28/2026 at 05:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BTIG sets a USD 6.00 target on October 27, 2026. For DarioHealth stock, revenue was USD 5.2 million in the second quarter of 2026.

Commercial evidence and reporting dates

BTIG initiated coverage on October 27, 2026, with a Buy rating.
Aon reviewed 17 studies on October 6, 2026, covering healthcare savings of 2.5 percent to 7.2 percent.
DarioHealth is scheduled to report its next quarterly results on November 11, 2026.

DRIO, US23725P3082, Illustration mit AI erstellt.

DarioHealth Corp. (ISIN US23725P3082) received a new USD 6.00 price target and Buy rating from BTIG on October 27, 2026, when the firm initiated coverage, according to Nasdaq. The analyst action gives the small digital-health company a fresh valuation reference ahead of its next quarterly report.

BTIG highlights growth potential

CNBC also reported the initiation on October 27, 2026, citing BTIG's USD 6.00 target for DarioHealth. The rating arrives as the company shifts toward recurring business with health plans, employers and provider-backed care.

In the second quarter of 2026, DarioHealth generated USD 5.2 million in revenue and lifted gross margin to 62 percent from 57 percent in the comparable period, according to the company's reported results listed in its DarioHealth investor release archive. Revenue reflected the strategic decision to discontinue certain pharmaceutical-related business.

What does the evidence mean?

The commercial case rests partly on healthcare savings. In a release dated October 6, 2026, DarioHealth said Aon reviewed 17 studies and estimated annual healthcare-cost reductions of 2.5 percent to 7.2 percent. The review also cited USD 5,077 in annual savings per Dario user with type 2 diabetes and 23.5 percent fewer inpatient discharges versus matched non-users. Aon stated that its review relied on materials identified or provided by Dario and did not independently audit the underlying studies.

Three dates frame the story

DarioHealth won a New Jersey health-plan contract on September 17, 2026, representing 1.5 million covered lives. On October 6, 2026, it published the Aon analysis covering 17 studies. On October 27, 2026, BTIG initiated coverage with a USD 6.00 target. This chronology links the contract opportunity, evidence package and new analyst view.

When are results due?

DarioHealth's next earnings announcement is scheduled for November 11, 2026, before the market opens, according to the Nasdaq report on the BTIG initiation. The date will provide the next formal test of revenue progress and margin performance.

Nasdaq valuation remains small

The latest primary-market quote was last at USD 3.48 on Nasdaq on October 27, 2026, at 4:00 p.m. ET. DarioHealth's market capitalization was USD 34.1 million, while its 52-week range was USD 3.01 to USD 16.44 as of that date. The valuation leaves the company sensitive to execution, customer additions and the timing of recurring-contract revenue.